Wenxiang Hu

Wenxiang Hu

Auto-generated profile, based on publicly available information

Wenxiang Hu

GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou National Laboratory, Guangzhou Medical University, Guangzhou, China

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2020 in Science
Verified
Journal Article
Closed access
PDF file
DGDongyin Guan
Dongyin Guan
YXYing Xiong
Ying Xiong
TTTrang Minh Trinh
Trang Minh Trinh
YXYang Xiao
Yang Xiao
WHWenxiang Hu
Wenxiang Hu
MLMitchell Avery Lazar
Mitchell Avery Lazar
The hepatocyte clock and food availability control gene expression and metabolism in nonhepatocytic cells in the liver.

7 September 2022 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
PDF file
WHWenxiang Hu
Wenxiang Hu
MLMitchell Avery Lazar
Mitchell Avery Lazar

8 February 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
YXYang Xiao
Yang Xiao
KBKirill Batmanov
Kirill Batmanov
WHWenxiang Hu
Wenxiang Hu
KZKun Zhu
Kun Zhu
ATAlexander Y. Tom
Alexander Y. Tom
MLMitchell Avery Lazar
Mitchell Avery Lazar
Current therapeutic strategies for treating nonalcoholic steatohepatitis (NASH) have failed to alleviate liver fibrosis, which is a devastating feature leading to hepatic dysfunction. Here, we integrated single-nucleus transcriptomics and epigenomics to characterize all major liver cell types during NASH development in mice and humans. The bifurcation of hepatocyte trajectory with NASH progression was conserved between mice and humans. At the nonalcoholic fatty liver (NAFL) stage, hepatocytes exhibited metabolic adaptation, whereas at the NASH stage, a subset of hepatocytes was enriched for the signatures of cell adhesion and migration, which were mainly demarcated by receptor tyrosine kinase ephrin type B receptor 2 (EphB2). EphB2, acting as a downstream effector of Notch signaling in hepatocytes, was sufficient to induce cell-autonomous inflammation. Knockdown of Ephb2 in hepatocytes ameliorated inflammation and fibrosis in a mouse model of NASH. Thus, EphB2-expressing hepatocytes contribute to NASH progression and may serve as a potential therapeutic target.

1 March 2022 in Genes & Development
Verified
Journal Article
Open access
PDF file
WHWenxiang Hu
Wenxiang Hu
CJChunjie Jiang
Chunjie Jiang
MKMindy Kim
Mindy Kim
YXYang Xiao
Yang Xiao
HRHannah J. Richter
Hannah J. Richter
MLMitchell Avery Lazar
Mitchell Avery Lazar
Peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor that is a vital regulator of adipogenesis, insulin sensitivity, and lipid metabolism. Activation of PPARγ by antidiabetic thiazolidinediones (TZD) reverses insulin resistance but also leads to weight gain that limits the use of these drugs. There are two main PPARγ isoforms, but the specific functions of each are not established. Here we generated mouse lines in which endogenous PPARγ1 and PPARγ2 were epitope-tagged to interrogate isoform-specific genomic binding, and mice deficient in either PPARγ1 or PPARγ2 to assess isoform-specific gene regulation. Strikingly, although PPARγ1 and PPARγ2 contain identical DNA binding domains, we uncovered isoform-specific genomic binding sites in addition to shared sites. Moreover, PPARγ1 and PPARγ2 regulated a different set of genes in adipose tissue depots, suggesting distinct roles in adipocyte biology. Indeed, mice with selective deficiency of PPARγ1 maintained body temperature better than wild-type or PPARγ2-deficient mice. Most remarkably, although TZD treatment improved glucose tolerance in mice lacking either PPARγ1 or PPARγ2, the PPARγ1-deficient mice were protected from TZD-induced body weight gain compared with PPARγ2-deficient mice. Thus, PPARγ isoforms have specific and separable metabolic functions that may be targeted to improve therapy for insulin resistance and diabetes.

17 April 2023 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
DGDongyin Guan
Dongyin Guan
HBHosung Bae
Hosung Bae
DZDishu Zhou
Dishu Zhou
YCYing Chen
Ying Chen
CJChunjie Jiang
Chunjie Jiang
MLMitchell Avery Lazar
Mitchell Avery Lazar
Rhythmic intraorgan communication coordinates environmental signals and the cell-intrinsic clock to maintain organ homeostasis. Hepatocyte-specific KO of core components of the molecular clock Rev-erbα and -β (Reverb-hDKO) alters cholesterol and lipid metabolism in hepatocytes as well as rhythmic gene expression in nonparenchymal cells (NPCs) of the liver. Here, we report that in fatty liver caused by diet-induced obesity (DIO), hepatocyte SREBP cleavage–activating protein (SCAP) was required for Reverb-hDKO–induced diurnal rhythmic remodeling and epigenomic reprogramming in liver macrophages (LMs). Integrative analyses of isolated hepatocytes and LMs revealed that SCAP-dependent lipidomic changes in REV-ERB–depleted hepatocytes led to the enhancement of LM metabolic rhythms. Hepatocytic loss of REV-ERBα and β (REV-ERBs) also attenuated LM rhythms via SCAP-independent polypeptide secretion. These results shed light on the signaling mechanisms by which hepatocytes regulate diurnal rhythms in NPCs in fatty liver disease caused by DIO.

6 July 2021 in Cell Metabolism
Verified
Journal Article
Closed access
WHWenxiang Hu
Wenxiang Hu
CJChunjie Jiang
Chunjie Jiang
MKMindy Kim
Mindy Kim
WYWenjian Yang
Wenjian Yang
KZKun Zhu
Kun Zhu
MLMitchell Avery Lazar
Mitchell Avery Lazar